Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
74.34
+2.12 (2.94%)
At close: Mar 23, 2026, 4:00 PM EDT
73.51
-0.83 (-1.12%)
After-hours: Mar 23, 2026, 7:57 PM EDT
Nektar Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Nektar Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $142, which forecasts a 91.01% increase in the stock price over the next year. The lowest target is $121 and the highest is $165.
Price Target: $142 (+91.01%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nektar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 2 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Mar 17, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $102 → $123 | Strong Buy | Maintains | $102 → $123 | +65.46% | Mar 16, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $105 → $150 | Strong Buy | Reiterates | $105 → $150 | +101.78% | Feb 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $135 → $165 | Strong Buy | Maintains | $135 → $165 | +121.95% | Feb 10, 2026 |
| BTIG | BTIG | Strong Buy Maintains $118 → $151 | Strong Buy | Maintains | $118 → $151 | +103.12% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
42.69M
from 55.23M
Decreased by -22.71%
Revenue Next Year
36.28M
from 42.69M
Decreased by -15.01%
EPS This Year
-9.81
from -9.73
EPS Next Year
-12.04
from -9.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 57.2M | 60.3M | |||
| Avg | 42.7M | 36.3M | |||
| Low | 23.5M | 7.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.5% | 41.3% | |||
| Avg | -22.7% | -15.0% | |||
| Low | -57.4% | -81.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | -7.01 | -8.18 | ||
| Avg | -9.81 | -12.04 | ||
| Low | -11.88 | -14.35 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.